COMPANY RESEARCHAUBE00 is an oral macrocyclic peptide in Phase 1. LUNA18 was discontinued in 2025; the company report confirms oral absorption in humans.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
AUBE00 is an oral pan-KRAS macrocyclic peptide from the SnipeTide platform; Phase 1 began in 2025.
LUNA18 was discontinued in 2025. The annual report states that human oral absorption was confirmed and development shifted to AUBE00. This is company-reported information, not publicly available quantitative clinical data.
As of 2026-09-30, the website also listed AQUA07, an oral macrocyclic allosteric ALK inhibitor. Its clinical stage was not confirmed in this review.
The July 24 company release confirms clinical entry; the Japanese registry identifies an oral Phase 1 study recruiting participants.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| AUBE00 | pan-KRAS（GDP） · Solid tumors | Phase 1 | No results found in this review |
| LUNA18 / paluratide | pan-RAS · Solid tumors | 已终止 | Human absorption reported by the company; quantitative data not disclosed |
| AQUA07 | Allosteric ALK · ALK-positive non-small cell lung cancer | Phase 1 | No results found in this review |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Ahead of the AHA meeting, an original report reviewed enlicitide analyses across PREVENT cardiovascular risk groups and an open-label extension. LDL cholesterol reductions were broadly consistent across risk categories and persisted through Week 104. The extension selected participants who had tolerated and adhered to treatment and lacked a control group, limiting generalization of its long-term findings.
Aurinia reported LUPKYNIS net product sales of $232.4 million for the nine months ended September 30, 2026, up 18%, including $79.4 million in the third quarter, up 12%. Total company revenue also includes licensing, collaboration, and royalty income. These are commercialization results for an approved oral cyclic peptide, rather than a new indication approval or clinical endpoint readout.
A new review connects peptide structure, formulation, screening, and pharmacokinetic testing in an evidence-based framework for oral drug discovery. It distinguishes architecture-led libraries, oral optimization of existing hits, and hybrid approaches. The scope includes cyclic and noncyclic peptides; the proposed framework organizes development evidence rather than demonstrating a new therapy or clinical benefit.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
